ASH data highlights Castleman disease studies

Italian pharma major Recordati’s (RECI: MI) rare diseases subsidiary announced the presentation of new data detailing advances in the understanding of Castleman disease (CD), a group of rare immune system disorders characterized by abnormal lymph node enlargement and systemic inflammatory symptoms that can be potentially life-threatening. In a series of poster presentations at the 67th American Society of Hematology Annual Meeting (ASH) Annual Meeting in Orlando, Florida.

Researchers reported on their work to develop an artificial intelligence (AI) model to facilitate grading and diagnosis of CD; a real-world analysis of the morbidity burden and healthcare costs associated with idiopathic multicentric Castleman disease (iMCD); a retrospective analysis of pediatric data from the largest iMCD patient registry; and results from a 20-year cohort study supporting the clinical relevance of updated CD subtype classification.

The company presented: a novel AI-driven histopathology model that automatically scores Castleman tissue samples, which is being developed to facilitate grading and diagnosis of CD, Tthe largest real-world analysis to date of morbidity and financial burden in idiopathic multicentric Castleman disease (iMCD).